Profund Advisors LLC Acquires 1,543 Shares of Krystal Biotech, Inc. $KRYS

Profund Advisors LLC boosted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 26.7% in the third quarter, HoldingsChannel reports. The fund owned 7,313 shares of the company’s stock after acquiring an additional 1,543 shares during the period. Profund Advisors LLC’s holdings in Krystal Biotech were worth $2,432,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of KRYS. Silvant Capital Management LLC bought a new stake in Krystal Biotech during the second quarter worth about $30,000. Integrated Wealth Concepts LLC bought a new position in shares of Krystal Biotech during the second quarter valued at approximately $46,000. Western Wealth Management LLC purchased a new position in shares of Krystal Biotech during the first quarter valued at approximately $34,000. Signaturefd LLC lifted its holdings in shares of Krystal Biotech by 27.3% during the third quarter. Signaturefd LLC now owns 168 shares of the company’s stock valued at $56,000 after purchasing an additional 36 shares during the last quarter. Finally, USA Financial Formulas bought a new stake in shares of Krystal Biotech in the 1st quarter worth approximately $44,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $332.29 on Monday. The stock’s 50-day simple moving average is $337.46 and its two-hundred day simple moving average is $308.68. The stock has a market capitalization of $9.84 billion, a price-to-earnings ratio of 41.64 and a beta of 0.50. Krystal Biotech, Inc. has a 52-week low of $184.02 and a 52-week high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 2nd. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.79 by $0.26. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The firm had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 7.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on KRYS. Bank of America upped their price target on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. HC Wainwright reiterated a “buy” rating and set a $361.00 price objective on shares of Krystal Biotech in a research note on Thursday, October 15th. Royal Bank Of Canada started coverage on Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 target price on the stock. Weiss Ratings raised Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 23rd. Finally, Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $377.20.

Insider Activity at Krystal Biotech

In related news, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the sale, the insider directly owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.